Health ministry questions reliability of vasculitis drug approval data
Tavneos was launched in Japan in 2022 after being approved by the ministry. Its package insert listed liver dysfunction as a serious side effect.
Related discussion groups
No group discusses this yet. Start a discussion group and attach this story.
More news about Japan
- Wrong anthems played at Asian Para Games after mishap-marred Asian GamesWrong national anthems were played thrice at the Asian Para Games in Nagoya, forcing the city's mayor to apologise after similar blunders at the Asian Games.
- AUD/JPY Price Forecast: Edges lower to near 110.50, sustains modestly bearish outlookThe AUD/JPY cross trades in negative territory around 110.60 during the early European trading hours on Thursday. Hawkish remarks from Japanese authorities provide some support to the Japanese Yen...
- Most BOJ Watchers Expect Next Interest Rate Hike in DecemberMore than 80% of Bank of Japan watchers anticipate the central bank’s next interest rate increase will come in December, according to a recent survey. None expect a hike when the bank concludes its...
- Explainer | Dit is waarom Japan naar een maan van Mars reist
- Автосалон за модели на азиатски марки се открива днес в СофияИзложение за азиатски автомобили се открива в София. В "Интер Експо Център" до 26 октомври могат да се видят автомобили на над 20 концерна от Китай, Япония и Южна Корея. Ще има и тест драйв зона с...
- Japan life insurers’ bond-buying plans set to support JGBsInsurers have been net buyers of superlong government bonds for four months, a trend strategists say could provide an anchor in upcoming auctions.
- Japan startup touts AI for automakers to match Chinese car development pace
- Two Japanese climbers missing in Nepal — The Japan Times - UA.NEWSTwo Japanese climbers missing in Nepal — The Japan Times UA.NEWS